Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era-Reference-Cited by-同舟云学术

Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era

Published:2020-06-16 Issue:8 Volume:20 Page:829-830
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Galluzzo Marco¹²^ORCID,Tofani Lorenzo¹³^ORCID,Bianchi Luca¹³,Talamonti Marina¹³^ORCID

Affiliation:

1. Dermatology Unit, Fondazione Policlinico Tor Vergata, Rome, Italy

2. Department of Experimental Medicine, University of Rome “Tor Vergata”, Rome, Italy

3. Department of Systems Medicine, University of Rome “Tor Vergata”, Rome, Italy

Funder

Novartis

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2020.1779217

Reference14 articles.

1. World Health Organization. [cited 2020 May 26]. Available from: https://covid19.who.int.

2. Dermatologists and SARS‐CoV‐2: the impact of the pandemic on daily practice

3. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab′ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension

4. Should biologics for psoriasis be interrupted in the era of COVID-19?

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Psoriasis and biological drugs at the time of SARS-CoV-2 infection: a mini review outlining risk of infection, seroprevalence, and safety and efficacy of the BNT162b2 vaccine;Frontiers in Immunology;2024-01-30

2. Assessment of safety profile of secukinumab in real-world scenario using United States food and drug administration adverse event reporting system database;Scientific Reports;2024-01-12

3. Interleukin-17 Inhibitor in Treatment of Psoriasis during COVID-19 Pandemic: An Ambispective Study;JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH;2023

4. Risk of COVID-19 infection, hospitalization and mortality in psoriasis patients treated with interleukin-17 inhibitors: A systematic review and meta-analysis;Frontiers in Immunology;2022-10-21

5. A review of disease burden and clinical management for generalized pustular psoriasis in China;Expert Review of Clinical Immunology;2022-09-07